# Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C

> **NCT04666298** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 312 (actual)

## Conditions studied

- Hypercholesterolemia
- Heterozygous Familial Hypercholesterolemia

## Interventions

- **DRUG:** Inclisiran sodium
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04666298
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-29
- **Primary completion:** 2022-04-18
- **Final completion:** 2022-10-19
- **Target enrollment:** 312 (ACTUAL)
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04666298

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04666298, "Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04666298. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*